ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2590

Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Alexis Ogdie1, Mei Liu2, Meghan Glynn2, Kelechi Emeanuru2, Leslie R Harrold3, Sven Richter4, Benoit Guerette4 and Philip J. Mease5, 1University of Pennsylvania, Philadelphia, PA, 2Corrona, LLC, Waltham, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Celgene Corporation, Summit, NJ, 5Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, methotrexate (MTX), patient outcomes, psoriatic arthritis and registry

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was to examine the baseline characteristics and 6-month clinical assessments of patients with PsA who had oligoarthritis (≤4 swollen joints) and initiated treatment with apremilast (APR) or methotrexate (MTX) monotherapy in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry, a prospective, US-based observational cohort study. Patients initiating biologic disease-modifying anti-rheumatic drug (bDMARD) monotherapy were also examined as a point of reference.

Methods: Patients ≥18 years of age with PsA and oligoarthritis in the registry who initiated monotherapy with APR, MTX, or a bDMARD and had a 6-month follow-up visit between June 2014 and March 2018 were included in the analysis. Descriptive statistics were calculated for patients’ clinical characteristics and disease assessments at treatment initiation and at the 6-month follow-up visit.

Results: The analysis included 150 patients initiating therapy (APR: n=34; MTX: n=15; bDMARD: n=101). Among APR and MTX initiators, 80% and 20% received at least 1 prior bDMARD, respectively (Table 1). APR was associated with higher levels of disease activity at baseline, including higher swollen joint count, Clinical Disease Activity for Psoriatic Arthritis (cDAPSA) (moderate and high: 50% [APR] vs. 27% [MTX]) and disease impairments represented by numerically higher scores of patient-reported outcome (PRO) measures, including the HAQ. Taken together, results suggest that APR initiators had more refractory oligoarthritis compared with MTX initiators. Clinical assessments at the 6-month follow-up indicate that patients who initiated APR experienced numerically higher improvements in disease activity and various PRO measures compared with MTX, as well as achievement of ≤1 swollen joint, HAQ minimal clinically important difference, and cDAPSA remission or low disease activity (Table 2). Of note, results associated with bDMARDs were more comparable to that of APR.

Conclusion: In this analysis of the Corrona PsA/SpA Registry, APR monotherapy was more often used in patients with refractory oligoarthritis compared with MTX monotherapy. Despite this, the APR group experienced numerically greater improvements in disease activity measures. Improvements observed with APR in patients with long-standing disease and refractory oligoarthritis were modest and comparable to that of bDMARDs.

 


Disclosure: A. Ogdie, Pfizer, Novartis, 2,Abbvie, BMS, Lilly, Pfizer, Novartis, Takeda, 5; M. Liu, Corrona, LLC, 3; M. Glynn, Corrona, LLC, 3; K. Emeanuru, Corrona, LLC, 3; L. R. Harrold, Corrona, LLC, 1,Pfizer, Inc., 2,Roche, Bristol-Myers Squibb, 5,Corrona, LLC, University of Massachusetts Medical School, 3; S. Richter, Sven Richter, 3; B. Guerette, Celgene Corporation, 3; P. J. Mease, Janssen Research & Development, LLC, 2.

To cite this abstract in AMA style:

Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold LR, Richter S, Guerette B, Mease PJ. Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/descriptive-comparisons-of-the-impact-of-apremilast-and-methotrexate-monotherapy-in-patients-with-oligoarticular-psoriatic-arthritis-in-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/. Accessed February 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/descriptive-comparisons-of-the-impact-of-apremilast-and-methotrexate-monotherapy-in-patients-with-oligoarticular-psoriatic-arthritis-in-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.